Your position:www.healthoo.com >> EN >> EN >> Formulation >> Merck announces positive results from phase 2 KeyVibe-002 trial evaluating coformulation of vibostolimab pembrolizumab in previously treated patients with metastatic NSCLC >> article
 
Merck announces positive results from phase 2 KeyVibe-002 trial evaluating coformulation of vibostolimab pembrolizumab in previously treated patients with metastatic NSCLC
Editor:xuezhe     Clicks:58    Date:2023-12-8 14:56:51
Keyword: Merck
Healthoo Information:
Merck announces positive results from phase 2 KeyVibe-002 trial evaluating coformulation of vibostolimab pembrolizumab in previously treated patients with metastatic NSCLC
After registration, we will provide the sample reports and the more comprehensive consulting services for you.
UserName 
Contact:  Title: Mr.Ms.
Password  
Repeat password: 
Mobile 
Email 
Verification code: 
Company Name 
 
 E-mail:xuezhe@healthoo.com
 Tel.:86-10-68032463
  Our services:
 China Im\Ex data service
 Service fees of Chinese Vision
 Our service items
Online information introduction
Monthly information
Relative Information
  • Deqi Pharmaceutical Merck reached a global clinical cooperation
  • Merck to Acquire ADC Leader Seagen
  • Bayer, Merck Announced to Close Two Factories
  • Bayer, Merck Announced to Close Two Factories
  • Merck's clear vision in China
  • Merck Serono to set up new factory ...
  • Merck and Simcere launch JV in China
  • Merck and Simcere signed agreement to es...
  • Merck Serono to complete industry chain ...
  • Merck collaborates with Sinopharm to boost&nb...
  • Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
    Tel:+86-10-68032463